CHMP recommends GSK's two-dose Cervarix
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended a two-dose schedule for GlaxoSmithKline's cervical cancer vaccine Cervarix (human papillomavirus (types 16 and 18) vaccine, recombinant). The vaccine previously required a three-dose schedule.